Search results for: rare disease

Prescription price puzzles: the sky-high cost of O...

This article explores the significant disparities between the US and Europe regarding orphan drugs a...

Read more
The European Commission publish their proposal for...

The European Commission has published their proposal for revised pharmaceutical legislation to cover...

Read more
EU HTA and what it means for manufacturers

Oncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...

Read more
What has occurred in the past year in the Swedish ...

TLV unveils annual report, offering insights into trends and projects that have dominated the past y...

Read more
What early access opportunities exist for innovati...

Our Market Access experts investigate what early access opportunities are available in China to enab...

Read more
Biopharmas continue to offer hefty discounts to se...

Biopharmas offer significant discounts on their products in China, to try and score spots on the cou...

Read more
Germany – European joint assessment at deadlock ...

Germany's BPI and vfa advise that the implementation of the European Health Technology Assessment (E...

Read more
Reflecting on the Pricing & Market Access tren...

Our experts reflect on the trends that shaped the European pricing and market access landscape in 20...

Read more
PMA Insights: Week 44

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
France: An update on the transitional reimbursemen...

The aim of the transitional reimbursement mechanism (PECT) launched in February 2021, was to allow r...

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch